NCT00092911CompletedPhase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy And Safety Study of a Flexible Dose of DVS-233 SR in Adult Outpatients With Major Depressive Disorder
Wyeth is now a wholly owned subsidiary of Pfizer0 sites244 target enrollmentStarted: September 28, 2004Last updated:
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 3
- Status
- Completed
- Sponsor
- Enrollment
- 244
Study Overview
Brief Summary
The main objective of this study is to compare the antidepressant efficacy and safety of DVS-233 SR versus placebo in adult outpatients with Major Depressive Disorder.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Double
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Outpatients
- •Men and women age 18 years of age and older
- •Women of childbearing potential participating in the study must have a negative serum pregnancy test result at screening and use a medically acceptable form of contraception
Exclusion Criteria
- •Treatment with DVS-233 SR at any time in the past
- •Treatment with venlafaxine (immediate release [IR] or extended release [ER]) within 90 days of study day 1
- •Known hypersensitivity to venlafaxine (IR or ER)
- •Significant risk of suicide based on clinical judgment, including common
Investigators
Similar Trials
Completed
Phase 3
Study Evaluating DVS-233 SR In Adult Outpatients With Major Depressive DisorderMajor Depressive DisorderNCT00073762Wyeth is now a wholly owned subsidiary of Pfizer375
Completed
Phase 3
Study Evaluating DVS-233 SR In Adult Outpatients With Major Depressive DisorderMajor Depressive DisorderNCT00072774Wyeth is now a wholly owned subsidiary of Pfizer480
Completed
Phase 3
Study Evaluating the Efficacy and Safety of Desvenlafaxine Tablets in Adult Outpatients With Major Depressive DisorderDepressive Disorder, MajorNCT00300378Wyeth is now a wholly owned subsidiary of Pfizer480
Completed
Phase 3
Study Evaluating DVS-233 in Adult Outpatients With Major Depressive DisorderMajor Depressive DisorderNCT00063206Wyeth is now a wholly owned subsidiary of Pfizer247
Completed
Phase 3
Study Evaluating DVS-233 SR And Venlafaxine ER In Adult Outpatients With Major Depressive DisorderMajor Depressive DisorderNCT00090649Wyeth is now a wholly owned subsidiary of Pfizer369